tiprankstipranks
Kaken Pharmaceutical Co Ltd (JP:4521)
:4521
Japanese Market
4521
Kaken Pharmaceutical Co
RESEARCH TOOLSreports
Want to see JP:4521 full AI Analyst Report?

Kaken Pharmaceutical Co (4521) Ratios

0 Followers

Kaken Pharmaceutical Co Ratios

JP:4521's free cash flow for Q4 2025 was ¥0.50. For the 2025 fiscal year, JP:4521's free cash flow was decreased by ¥ and operating cash flow was ¥-0.30. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 26Mar 25Mar 24
Liquidity Ratios
Current Ratio
 ― 3.67 4.52 5.62 5.27
Quick Ratio
 ― 3.04 3.60 4.72 4.53
Cash Ratio
 ― 1.78 2.15 2.66 2.86
Solvency Ratio
 ― 0.44 0.18 0.39 0.27
Operating Cash Flow Ratio
 ― 0.98 -0.53 0.14 0.44
Short-Term Operating Cash Flow Coverage
 ― 7.74 -2.88 0.67 2.40
Net Current Asset Value
¥ ―¥ 73.59B¥ 63.46B¥ 79.11B¥ 80.41B
Leverage Ratios
Debt-to-Assets Ratio
 ― 0.02 0.02 0.02 0.02
Debt-to-Equity Ratio
 ― 0.03 0.03 0.03 0.03
Debt-to-Capital Ratio
 ― 0.02 0.03 0.03 0.03
Long-Term Debt-to-Capital Ratio
 ― 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 ― 1.25 1.21 1.19 1.22
Debt Service Coverage Ratio
 ― 4.26 0.58 2.79 2.08
Interest Coverage Ratio
 ― 751.29 -19.98 559.59 470.47
Debt to Market Cap
 ― 0.02 0.02 0.03 0.03
Interest Debt Per Share
 ― 101.62 102.74 102.47 102.93
Net Debt to EBITDA
 ― -2.28 -16.84 -3.72 -5.93
Profitability Margins
Gross Profit Margin
―61.96%51.05%53.49%54.20%
EBIT Margin
―20.70%-1.17%13.62%9.36%
EBITDA Margin
―23.42%3.16%17.45%12.88%
Operating Profit Margin
―22.37%-1.17%13.20%10.96%
Pretax Profit Margin
―20.67%3.01%13.60%9.34%
Net Profit Margin
―14.83%2.79%11.14%7.45%
Continuous Operations Profit Margin
―14.83%2.79%11.14%7.45%
Net Income Per EBT
―71.75%92.69%81.92%79.80%
EBT Per EBIT
―92.39%-257.29%102.97%85.23%
Return on Assets (ROA)
―7.32%1.20%4.68%3.27%
Return on Equity (ROE)
―9.14%1.45%5.58%3.99%
Return on Capital Employed (ROCE)
―13.14%-0.57%6.23%5.50%
Return on Invested Capital (ROIC)
―9.21%-0.52%4.98%4.27%
Return on Tangible Assets
―8.15%1.39%4.89%3.41%
Earnings Yield
―8.15%1.37%6.13%3.92%
Efficiency Ratios
Receivables Turnover
 ― 4.44 3.38 3.03 3.79
Payables Turnover
 ― 4.30 4.97 4.72 5.45
Inventory Turnover
 ― 1.88 1.97 1.95 2.15
Fixed Asset Turnover
 ― 3.40 2.83 2.84 2.86
Asset Turnover
 ― 0.49 0.43 0.42 0.44
Working Capital Turnover Ratio
 ― 1.11 1.00 0.81 0.81
Cash Conversion Cycle
 ― 191.36 220.03 229.98 199.36
Days of Sales Outstanding
 ― 82.20 108.01 120.30 96.36
Days of Inventory Outstanding
 ― 194.07 185.40 187.02 169.93
Days of Payables Outstanding
 ― 84.91 73.39 77.34 66.93
Operating Cycle
 ― 276.27 293.42 307.31 266.29
Cash Flow Ratios
Operating Cash Flow Per Share
 ― 780.36 -292.23 68.29 246.28
Free Cash Flow Per Share
 ― 671.92 -371.26 10.86 187.56
CapEx Per Share
 ― 108.43 79.03 57.42 58.72
Free Cash Flow to Operating Cash Flow
 ― 0.86 1.27 0.16 0.76
Dividend Paid and CapEx Coverage Ratio
 ― 2.63 -1.17 0.33 1.18
Capital Expenditure Coverage Ratio
 ― 7.20 -3.70 1.19 4.19
Operating Cash Flow Coverage Ratio
 ― 7.74 -2.88 0.67 2.40
Operating Cash Flow to Sales Ratio
 ― 0.32 -0.14 0.04 0.13
Free Cash Flow Yield
―14.99%-8.97%0.31%5.08%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― 12.26 73.21 16.30 25.52
Price-to-Sales (P/S) Ratio
 ― 1.82 2.04 1.82 1.90
Price-to-Book (P/B) Ratio
 ― 1.12 1.06 0.91 1.02
Price-to-Free Cash Flow (P/FCF) Ratio
 ― 6.67 -11.15 319.11 19.70
Price-to-Operating Cash Flow Ratio
 ― 5.74 -14.17 50.77 15.00
Price-to-Earnings Growth (PEG) Ratio
 ― 0.17 -0.87 0.35 -0.60
Price-to-Fair Value
 ― 1.12 1.06 0.91 1.02
Enterprise Value Multiple
 ― 5.48 47.85 6.69 8.84
Enterprise Value
 ― 120.76B 116.09B 84.06B 83.11B
EV to EBITDA
 ― 5.48 47.85 6.69 8.84
EV to Sales
 ― 1.28 1.51 1.17 1.14
EV to Free Cash Flow
 ― 4.71 -8.25 205.02 11.79
EV to Operating Cash Flow
 ― 4.06 -10.48 32.62 8.98
Tangible Book Value Per Share
 ― 3.49K 3.25K 3.61K 3.46K
Shareholders’ Equity Per Share
 ― 4.00K 3.89K 3.81K 3.63K
Tax and Other Ratios
Effective Tax Rate
 ― 0.28 0.07 0.18 0.20
Revenue Per Share
 ― 2.46K 2.03K 1.91K 1.94K
Net Income Per Share
 ― 365.42 56.55 212.66 144.79
Tax Burden
 ― 0.72 0.93 0.82 0.80
Interest Burden
 ― 1.00 -2.57 1.00 1.00
Research & Development to Revenue
 ― 0.20 0.27 0.17 0.22
SG&A to Revenue
 ― 0.20 0.25 <0.01 0.00
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 2.14 -5.17 0.32 1.36
Currency in JPY